https://www.selleckchem.com/products/ON-01910.html
Twenty-three patients were evaluable for response and PFS; 15 (65%) had a partial response, 7 (30%) stable, 1 (4%) progressive disease with an objective response rate of 65%; 71% in ovarian and 50% in endometrial cancer. Median progression free survival (PFS) is 12.4 months; 14.0 months in endometrial cancer, 7.2 months in ovarian cancer; 54% had a PFS 6 months. The median duration of response for PR patients (n = 15) was 10.9 months. The regimen was tolerable with manageable side effects. Encouraging activity was observed in endo
Like
Comment
Share
